Evidence map›Paper›PMID 36466105›Full record

ArticleEuroasian journal of hepato-gastroenterology2022

Outcomes after Liver Transplantation with Steatotic Grafts: Redefining Acceptable Cutoffs for Steatotic Grafts.

Ben L Da, Jinendra Satiya, Rajiv P Heda, Yu Jiang, Lawrence F Lau, Ahmed Fahmy, Aaron Winnick, Nitzan Roth, Elliot Grodstein, Paul J Thuluvath and 4 more

Abstract read
In one paragraph

Article in Euroasian journal of hepato-gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ben L DaDivision of Hepatology, Department of Internal Medicine, Sandra Atlas Bass Center for Liver Diseases and Transplantation, Barbara and Zucker School of Medicine for Hofstra/Northwell Health, Manhasset, New York, United States of America.ORCID https://orcid.org/0000-0002-7750-240X
Jinendra SatiyaDivision of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America.ORCID https://orcid.org/0000-0001-5479-2312
Rajiv P HedaDepartment of Internal Medicine, Tulane University, New Orleans, Louisiana, United States of America.
Yu JiangSchool of Public Health, University of Memphis, Memphis, Tennessee, United States of America.
Lawrence F LauDivision of Transplant, Northwell Health System Transplant Center, Northshore University Hospital, Northwell Health, Manhasset, New York, United States of America.
Ahmed FahmyDivision of Transplant, Northwell Health System Transplant Center, Northshore University Hospital, Northwell Health, Manhasset, New York, United States of America.
Aaron WinnickDivision of Transplant, Northwell Health System Transplant Center, Northshore University Hospital, Northwell Health, Manhasset, New York, United States of America.
Nitzan RothDivision of Hepatology, Department of Internal Medicine, Sandra Atlas Bass Center for Liver Diseases and Transplantation, Barbara and Zucker School of Medicine for Hofstra/Northwell Health, Manhasset, New York, United States of America.
Elliot GrodsteinDivision of Transplant, Northwell Health System Transplant Center, Northshore University Hospital, Northwell Health, Manhasset, New York, United States of America.
Paul J ThuluvathInstitute of Digestive Health and Liver Disease, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
Ashwani K SingalDivision of Gastroenterology and Hepatology, University of South Dakota, Avera McKenna University Health Center and Transplant Institute, Sioux Falls, South Dakota, United States of America.
Thomas D SchianoDivision of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, United States of America.
Lewis W TepermanDivision of Transplant, Northwell Health System Transplant Center, Northshore University Hospital, Northwell Health, Manhasset, New York, United States of America.
Sanjaya K SatapathyDivision of Hepatology, Department of Internal Medicine, Sandra Atlas Bass Center for Liver Diseases and Transplantation, Barbara and Zucker School of Medicine for Hofstra/Northwell Health, Manhasset, New York, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Graft macrosteatosis can predispose to a higher risk of graft loss so we sought to redefine acceptable cutoffs for graft steatosis. Methods: Data of 26,103 donors who underwent liver transplantation (LT) between January 2004 and December 2018 from the UNOS-STAR database were utilized. A high-risk steatotic (HRS) graft and a low-risk steatotic (LRS) graft were defined as ≥20% and <20% macrosteatosis, respectively. High-risk steatotic grafts were further classified as grafts with 20-29% (G1S grafts), 30-39% (G2S grafts), and ≥40% steatosis (G3S grafts). Outcomes between groups were compared. Results: LRS grafts had excellent graft (93.3 and 87.7%) and overall survival (95.4 and 90.5%) at 90 days and 1 year. Compared to LRS grafts, G1S, G2S, and G3S grafts had worse graft and overall survival at 90 days and 1-year ( Discussion: Liver grafts can be categorized into three categories: (1) <20% or "very low risk", (2) 20-39% or "low-to-moderate risk", and usually acceptable, and (3) ≥40% steatosis or "moderate-to-high risk". How to cite this article: Da BL, Satiya J, Heda RP,

Indexed as

AllograftsDonor selectionFatty liverLiver transplantationTissue and organ procurement

Identifiers

PMID36466105
PMCPMC9681573

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.